Dr. Pishvaian is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5255 Loughboro Road Northwest
Washington, DC 20016Phone+1 202-660-6500Fax+1 202-660-6501
Education & Training
- MedStar Health/Georgetown University HospitalFellowship, Hematology and Medical Oncology, 2004 - 2007
- MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 2001 - 2004
- Georgetown UniversityPh.D., Cell Biology/Tumor Biology, 1993 - 2001
- Georgetown University School of MedicineClass of 2001
- Duke UniversityBS, Biology, Cum Laude, 1989 - 1993
Certifications & Licensure
- MD State Medical License 2010 - 2025
- DC State Medical License 2004 - 2024
- TX State Medical License 2019 - 2021
- VA State Medical License 2001 - 2010
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- First Place Award Winner Department of Internal Medicine �Research Day�, 2007
- Honors Certificate in Cell and Molecular Biology 1993
- Dean�s List 1990
Clinical Trials
- A Study of Temsirolimus Plus Capecitabine in Patients With Advanced Cancer Start of enrollment: 2010 Jul 01
- A Study of Gemcitabine and Cyberknife Radiation Therapy for Pancreatic Cancer Start of enrollment: 2009 Nov 01
- A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer Start of enrollment: 2009 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 93 citationsPembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study.Janice M. Mehnert, Emily K. Bergsland, Bert H. O'Neil, Armando Santoro, Jan H.M. Schellens
Cancer. 2020-07-01 - 24 citationsDecrease in blood miR-296 predicts chemotherapy resistance and poor clinical outcome in patients receiving systemic chemotherapy for metastatic colon cancerN. Shivapurkar, Sameh Mikhail, R. Navarro, W. Bai, John Marshall
International Journal of Colorectal Disease. 2013-06-01 - 96 citationsDisruption of transforming growth factor-β signaling through β-spectrin ELF leads to hepatocellular cancer through cyclin D1 activationKrit Kitisin, Natarajan Ganesan, Yi Tang, Wilma Jogunoori, Eugene A. Volpe
Oncogene. 2007-11-01
Journal Articles
- Entrectinib in TRK and ROS1 Fusion-Positive Metastatic Pancreatic CancerPishvaian MJ, Garrido-Laguna I, Liu SV, Multani PS, Chow-Maneval E, Rolfo C., JCO Precision Oncology, 1/1/2018
- Five-Fraction Stereotactic Body Radiation Therapy (SBRT) and Chemotherapy for the Local Management of Metastatic Pancreatic CancerJohn Marshall, Sean Collins, Keith Unger, Aidan Burke, Marie Gurka, Michael Pishvaian, Journal of Gastrointestinal Cancer
- Pharmacogenomic characterization of gemcitabine response--a framework for data integration to enable personalized medicineHarris M, Bhuvaneshwar K, Natarajan T, Sheahan L, Wang D, Tadesse MG, Shoulson I, Filice R, Steadman K, Pishvaian MJ, Madhavan S, Deeken J., Pharmacogenet Genomics, 1/1/2014
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Association of DNA damage response and repair genes (DDR) mutations and microsatellite instability (MSI), PD-L1 expression, tumor mutational burden (TMB) in gastroesop...Michael Cerniglia, Joanne Xiu, Axel Grothey, Michael J. Pishvaian, Jimmy J. Hwang, John Marshall, Ari M. Vanderwalde, Anthony Frank Shields, Heinz-Josef Lenz, Mohamed ..., Gastrointestinal Cancers Symposium, J Clin Oncol, 1/1/2019
- Outcomes in pancreatic adenocarcinoma (PDA) patients (pts) with genetic alterations in DNA damage repair (DDR) pathways: Results from the Know Your Tumor (KYT) programMichael J. Pishvaian, Edik Matthew Blais, Jonathan Robert Brody, Davendra Sohal, Andrew Eugene Hendifar, Vincent Chung, Sameh Mikhail, Lola Rahib, Emily Lyons, Lisa Ti..., Gastrointestinal Cancers Symposium, J Clin Oncol, 1/1/2019
- A phase I/II study of ribociclib plus everolimus in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) refractory to chemotherapy.Benjamin Adam Weinberg, Hongkun Wang, Agnieszka Katarzyna Witkiewicz, John Marshall, Erik S. Knudsen, Michael J. Pishvaian., J Clin Oncol, 1/1/2018
- Join now to see all
Lectures
- Improved overall survival (OS) for advanced pancreatic cancer (PDAC) patients (pts) enrolled in the Know Your Tumor (KYT) program whose tumors harbored highly actionab...2019 ASCO Annual Meeting - 6/1/2019
- Final report of a phase I/II study of veliparib (Vel) in combination with 5-FU and oxaliplatin (FOLFOX) in patients (pts) with metastatic pancreatic cancer (mPDAC).2019 ASCO Annual Meeting - 6/1/2019
- Precision Medicine in GI Cancers: Targeting the DNA Damage Repair PathwayMD Anderson Cancer Center - 1/1/2018
- Join now to see all
Other
- Precision Medicine for Pancreatic CancerPancreatic Cancer Action Network Webinar
Washington, DC - 1/1/2017 - Epidermal Growth Factor InhibitorsPishvaian M, Wang D, He R, Marshall JL, Encyclopedia of Cancer
1/1/2009 - Molecularly Targeted Therapy for Metastatic Colon Cancer: Proven Treatments and Promising New AgentsPishvaian, MJ and Wellstein, A, Cancernetwork.com
1/1/2008
Press Mentions
- Targeted Therapy May Increase Overall Survival in Patients with Pancreatic CancerMarch 3rd, 2020
- Platinum-Based Therapy Can Significantly Improve Survival for Some Pancreatic Cancer PatientsAugust 27th, 2019
- Supreme Court: Ginsburg Treated for Tumor on PancreasAugust 23rd, 2019
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: